Text Size

Blood Test to Measure DNA Damage in Blood

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Alberta Health Services
ClinicalTrials.gov Identifier:
NCT00523471
First received: August 30, 2007
Last updated: April 4, 2012
Last verified: April 2012
History of Changes
  Purpose

To check the radiosensitivity level in individual patients based on their DNA damage level.


Condition Intervention
Prostate Cancer
 Procedure: Blood test

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Alberta Health Services:

Enrollment: 40
Study Start Date: July 2007
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

community sample

Criteria

Inclusion Criteria:

  • prostate cancer diagnosis
  • undergoing radiotherapy
  • agree to participate in study

Exclusion Criteria:

  • not willing to participate
  • not undergoing radiotherapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00523471

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
Alberta Health Services
Investigators
Principal Investigator: Nadeem Pervez, MBBS, FRCPC Alberta Health Services
  More Information

No publications provided

Responsible Party: Alberta Health Services
ClinicalTrials.gov Identifier: NCT00523471     History of Changes
Other Study ID Numbers: GU-6-0076/ethics 23586
Study First Received: August 30, 2007
Last Updated: April 4, 2012
Health Authority: Canada: Health Canada

Keywords provided by Alberta Health Services:
prostate cancer
gamma H2AX
radiosensitivity

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
 Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on May 23, 2013